Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth-containing quadruple therapy with rabeprazole, cefuroxime, and doxycycline for first-line H. pylori eradication in penicillin-allergic patients
ChiCTR2300076151Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rabeprazole, cefuroxime, doxycycline and bismuth subsalicylate in Helicobacter pylori infection, sponsored by First Affiliated Hospital of Ningbo University. Primary endpoint: Eradication rates of Helicobacter pylori. Started Sep 2023; status: recruiting.
02
Drugs
rabeprazolecefuroximedoxycyclinebismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300076151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076151.